Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002681801 | SCV002995104 | uncertain significance | not provided | 2022-05-29 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. This variant has not been reported in the literature in individuals affected with SCNN1A-related conditions. This variant is present in population databases (rs759745474, gnomAD 0.03%). This sequence change replaces alanine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 43 of the SCNN1A protein (p.Ala43Val). |
Ambry Genetics | RCV004066912 | SCV004946085 | uncertain significance | Inborn genetic diseases | 2024-02-21 | criteria provided, single submitter | clinical testing | The c.128C>T (p.A43V) alteration is located in exon 2 (coding exon 1) of the SCNN1A gene. This alteration results from a C to T substitution at nucleotide position 128, causing the alanine (A) at amino acid position 43 to be replaced by a valine (V). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV005008695 | SCV005629589 | uncertain significance | Pseudohypoaldosteronism, type IB1, autosomal recessive; Bronchiectasis with or without elevated sweat chloride 2; Liddle syndrome 3 | 2023-12-29 | criteria provided, single submitter | clinical testing |